The shingles vaccine may reduce the risk of dementia
Evidence that the shingles vaccine may lower dementia risk by around 20% is prompting interest but also skepticism about whether the effect is causal or just a byproduct of “healthy vaccinee” bias and study design quirks. Participants weigh this potential brain benefit against the known value of preventing shingles itself, sharing painful personal cases and frustrations with age-based eligibility, cost, and access in different health systems. The exchange broadens to other vaccines linked to reduced dementia risk, the limits of observational data, and how infections and immune function might factor into neurodegeneration more generally.
Study findings & proposed dementia benefit
- Thread centers on observational studies suggesting shingles vaccination reduces dementia risk by ~20%, with absolute reductions of ~2–3.5% over ~5–7 years in several countries.
- Other interventions with similar reported impact are mentioned: treatment of depression, more education, correcting hearing loss, reducing obesity, and limiting alcohol.
Evidence quality and skepticism
- Multiple commenters stress that the dementia effect is an association, not proof of causation.
- A linked presentation argues the apparent benefit of the older live vaccine (Zostavax) was a statistical artifact (healthy-vaccinee and diagnosis bias).
- For Shingrix, some see promising quasi‑experimental data from UK age‑cutoff policies; others say results are small, sex‑specific (mostly in women), and potentially sensitive to analysis choices.
- Strong emphasis on being wary of causal claims from observational studies and on the need for RCTs.
When to get the shingles vaccine
- Official recommendations (often 50+; UK 65+) frustrate people who had shingles or have high dementia anxiety in their 30s–40s.
- Concerns that getting it “too early” could mean waning protection in old age; unclear policies on boosters. Some doctors advise waiting; others vaccinate earlier, especially with risk factors.
Access, policy, and cost
- Experiences vary by country: some systems refuse vaccination below guideline age even for cash; others are flexible via private or travel clinics.
- In the US, people often can get it off‑label if they pay or find a willing prescriber; cost cited around $500 for two Shingrix doses.
- Insurance coverage typically tied to age or comorbidities.
Side effects and risks
- Many report strong but short‑lived systemic reactions (fever, malaise, significant arm pain).
- Package‑insert warning about increased Guillain‑Barré risk is noted; some describe long‑term local pain.
- One commenter links shingles reactivation to COVID vaccination.
Broader context: infections, vaccines, and dementia
- Some clinicians mention influenza and pneumococcal vaccines being associated with reduced Alzheimer’s; others attribute this to healthy‑vaccinee bias.
- Infections, especially severe ones and possibly frequent respiratory illnesses, are discussed as potential contributors to later dementia, but the strength of evidence is disputed.
Personal experiences with shingles
- Numerous anecdotes of shingles in 20s–40s and even teens, sometimes with permanent nerve damage or sensory loss.
- Several people with severe postherpetic neuralgia urge others to get vaccinated and to seek antivirals quickly if shingles appears.